Performance and Quality Control of the 99Mo/99mTc Generator
- 1.9k Downloads
Generator function and the purity of 99mTc eluates of the available fission 99Mo generators in Europe have been investigated by several European research institutions over the years. Much information on the benefits of improved technology has been documented, testifying to high standards of manufacturing and to the reliability of validation processes implemented by the regulatory agencies for safe application of the 99Mo/99mTc generator in nuclear medicine.
Several European centers were engaged in implementing GMP standards for the preparation of 99mTc radiopharmaceuticals in nuclear medicine, and thus have contributed to establish a protocol for analytical procedures, which can validate the performance of generator systems from different manufacturers and assure the quality of short-lived generator eluates. The protocol is presented in Appendix Al of this chapter.
KeywordsElution Efficiency Daughter Activity Daughter Radionuclide Radionuclide Generator Sodium Pertechnetate
Unable to display preview. Download preview PDF.
- Boyd RE (1973) Recent developments in generators of 99mTc (IAEA-SM-171/94) In: Radiopharmaceuticals & labelled compounds 1973. IAEA Vienna, pp 3–26Google Scholar
- Boyd RE, Hetherington ELR, Moore PW (1985) Radionuclide generator technology. In: Radiophar-maceuticals & labelled compounds 1984. IAEA Vienna, 79–94Google Scholar
- Brandau W, Hotze L-A, Meyer G-J (1996) Radiochemie. In: Bull U, Schicha H, Biersack H-J, Knapp WH, Reiners Chr, Schober O (eds) Nuklearmedizin [in German]. Georg Thieme, Stuttgart, pp 79–113Google Scholar
- Council of Europe (2005a) Sodium pertechnetate[99mTc] injection (fission). Monograph No. 124. European Pharmacopoeia, 5th edn., Maisonneuve, Sainte-RuffineGoogle Scholar
- Council of Europe (2005b) Sodium pertechnetate[99mTc] injection (nonfission). Monograph No. 283. European Pharmacopoeia, 5th edn. Maisonneuve, Sainte-RuffineGoogle Scholar
- Feigl F (1958) Spot tests in inorganic analysis, 5th edn. Elsevier, Amsterdam, p. 145Google Scholar
- Hammermaier A, Reich E, Endrulat HJ, Bögl W (1985) Investigations on the quality of eluates from seven fission Mo-99/Tc-99m-generators. Institute for Radiation Hygiene of the Federal Health Office, Neuherberg, Germany. ISH Report 64.Google Scholar
- Marengo M, Aprile C, Bagnara C, Bolzati C, Bonada C, Candini G, Casati R, Civollani S, Colombo FR, Compagnone G, Del Dottore F, Di Guglielmo E, Ferretti PP, Lazzari S, Minoia C, Pancaldi D, Ronchi A, Sanita di Toppi G, Saponaro R, Torregiani T, Uccelli L, Vecchi F, Piffanelli A (1999) Quality control of 99Mo/99mTc-generators: results of a survey of the radiopharmacy working group of the Italian Association of Nuclear Medicine (AIMN) Nucl Med Commun 20:1077–1084Google Scholar
- Nordic Council on Medicines (1989) Nordic guidelines. Radiopharmacy — preparation and control of radiopharmaceuticals in hospitals. NLN Publication No. 26, UppsalaGoogle Scholar
- Ponto JA, Swanson DP, Freitas JE (1987) Clinical manifestations of radio-pharmaceutical formulation problems. In: Hladik WB III, Saha GB, Study KT (eds) Essentials of nuclear medicine science. Williams & Wilkins, Baltimore, pp 270–274Google Scholar
- Richards P (1966) Nuclide generators. In: Radioactive Pharmaceuticals. USAEC Symposium Series, No. 6, (CONF-651111). Oak Ridge, Tennessee, pp 155–163Google Scholar
- Robson J (1972) Process for the production of technetium-99m from neutron irradiated molybdenum trioxide — assigned to the AAEC patents: UK (40273/72), USA (284,868), Sweden (10868/ 72), Japan (85901/1972)Google Scholar
- United States Pharmacopeial Convention (2005) Official monographs: USP 28, sodium pertechnetate Tc99m injection. United States pharmacopeia (USP) 28 — national formulary (NF) 23, p 1861Google Scholar